A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 17300 participants.
Also called NCT06292013
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 17,300 participants
- Sponsor
- Registry
-
NCT06292013 -
2023-509190-23
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Slovakia, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06292013. Randomized; double masking; primary purpose treatment. Start 2024-03-05 (actual); primary completion 2029-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
- Condition
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Condition
- Elevated Lp(a)
- Intervention (Drug)
- Lepodisiran Sodium
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06292013- Content hash
0d3ebb4d791d4016a9eae3bb3f77d564eb28e62d6aed1f17c9374ec3c2d8286a